logo
Sugar cookies sold at Target in 20 states recalled over fears of wood chip contamination

Sugar cookies sold at Target in 20 states recalled over fears of wood chip contamination

Yahoo2 days ago
Target has recalled sugar cookies sold in 20 states over fears of wood chip contamination.
More than 800 cases of Favorite Day Bakery Frosted Sugar Cookies were recalled by the retailer on July 22.
The cookies, which come in a 10-count box, were sold to stores in Washington D.C., and the following states:
Connecticut
Delaware
Illinois
Indiana
Kentucky
Massachusetts
Maryland
Maine
Michigan
Missouri
North Carolina
New Jersey
New York
Ohio
Pennsylvania
Rhode Island
Tennessee
Virginia
Vermont
The Food and Drug Administration classified the recall as Class II, which means the product 'may cause temporary or medically reversible adverse health consequences.'
The Independent has reached out to Target for comment.
Target has also recently recalled other grocery products, including the High Noon Vodka Seltzer Beach 12-Pack.
The alcoholic seltzers were recalled on July 29 after it was found that some of the variety packs contained Celsius Astro Vibe energy drink cans that were accidentally filled with vodka seltzer.
At the time of the recall, there were no reported illnesses or adverse events from the products.
A representative for High Noon previously told The Independent: 'We are working with the FDA, retailers and distributors to proactively manage the recall to ensure the safety and well-being of our consumers. The states that may be impacted are: Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia and Wisconsin.'
Over 300,000 kitchen step stools sold at stores, including Target, Walmart and Home Depot, were also recently recalled due to safety concerns.
The Cosco 2-Step Kitchen Stepper was recalled on July 31 after 34 reports of the stool's safety bar detaching or breaking, including two incidents that resulted in head injuries.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Should You Take a Vitamin B12 Supplement?
Should You Take a Vitamin B12 Supplement?

Yahoo

time33 minutes ago

  • Yahoo

Should You Take a Vitamin B12 Supplement?

Credit - Photo-Illustration by TIME (Source Images: eyenigelen/Getty Images, Sersol/Getty Images) Everyone needs vitamin B12: It helps the body produce red blood cells and maintain healthy brain function, along with so many other things. But are you getting enough of it? Here's what to know about vitamin B12 and whether you should consider upping your levels. A boon for brain health 'Vitamin B12 is important for brain health because it helps protect nerve cells in the brain, which support memory and thinking skills,' says Michelle Routhenstein, a preventive cardiology dietitian and certified diabetes educator in New York. It's water-soluble, so the body does not store it in large amounts, and daily intake is essential. The current federal recommendations are for adults to get 2.4 mcg of vitamin B12 per day. Great food sources of B12 include seafood like oysters, salmon and tuna, beef, and fortified products like nutritional yeast, plant-based milks, some breads and breakfast cereals, says Routhenstein. But some recent research suggests that some people may need even more than that. Vitamin B12 deficiencies can impact your brain function even when your intake levels are considered normal, says Dr. Ari J. Green, a professor at the University of California, San Francisco's department of ophthalmology. In a recent study, Green and his colleagues found that people with B12 levels that were technically normal but on the lower end of the range had impaired brain function. 'We could detect neurological impairment at levels currently considered 'normal,' independently of other factors like years of education," particularly in older people, says Dr. Alexandra Beaudry-Richard, a resident at McGill University and co-author of the study. 'To us, this should reinvigorate a conversation about how much B12 is needed for optimal neurological function.' Read More: Should You Take a Vitamin D Supplement? Other studies have found that people with Alzheimer's disease and mild cognitive impairment tend to have lower B12 levels—and supplementation with B12 can reduce the rate of brain atrophy. However, on the opposite end, the study showed signs of a possible detrimental effect on the brain when people had high B12 levels in their blood. 'This warrants further studies to evaluate what healthy B12 levels are on both ends of the spectrum,' says Dr. Ahmed Abdelhak, one of the study's authors and a clinical instructor in neurology at UCSF School of Medicine. Should you take a B12 supplement? You can (and should) get B12 from your diet, but some people may have a tough time getting adequate levels of the nutrient from food alone. Older adults are more likely to develop vitamin B12 deficiencies because the vitamin requires stomach acid to be absorbed, and stomach acid production starts to decline with age. Routhenstein recommends people look closer into their B12 status starting around age 50 or if they are at higher risk of a B12 deficiency. This category includes vegans and vegetarians, people taking specific medications that interfere with B12 absorption such as metformin or proton pump inhibitors, and those who have gastrointestinal disorders like Crohn's, celiac, or atrophic gastritis. You can get tested for a vitamin B12 deficiency at your annual physical. If you are deficient, your doctor might recommend supplementation. Read More: 7 Surprising Symptoms of Lyme Disease The UCSF study authors recommend checking levels starting at age 70, but you can get it checked on a standard blood test at any age through your primary care physician. Dr. Ralph Green, a professor of pathology and lab medicine at the University of California, Davis—and another author on that recent study—says that checking B12 may also be valuable for people who have unexplained symptoms that have been linked to B12 deficiency. For those with declining gastric function, he says taking supplements is likely the best way to promote absorption, and the level of supplementation a person should consume depends on whether their absorption is normal or not. Pregnant women, too, need higher B12 intake to support fetal brain development; if you're pregnant, consult with your ob-gyn about optimal B12 levels for you. What kind of B12 supplement is best? B12 in supplements and fortified foods can be more easily absorbed than from food, especially for older adults and those with absorption issues, says Routhenstein. If your doctor has advised you to take a B12 supplement, it's best to ask them to recommend specific dosages and brands. But Routhenstein recommends following these general guidelines when selecting a B12 supplement. Always look for those with methylcobalamin on the label, as this is the most bioavailable form of B12, meaning the body can absorb it the best. It's also the optimal form for heart and brain health and nerve function, she says. Sublingual (under the tongue) or liquid B12 is often touted for better absorption. This form of B12 does so 'by bypassing the digestive system and entering the bloodstream directly,' says Routhenstein. Of course, no supplement is a cure-all, and there are other ways to support brain health, including maintaining a healthy diet and exercise regimen. Activities that stimulate multiple brain areas simultaneously are excellent at promoting cognitive longevity, Beaudry-Richard says. Practicing a musical instrument, dancing, and studying a foreign language daily, for example, all recruit 'brain circuits responsible for vision, hearing, movement, emotions' and more. 'It's like a full-body workout for the brain,' she says. Contact us at letters@

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Yahoo

time33 minutes ago

  • Yahoo

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly's recent setback and expand treatment options beyond injections. The study, which began in January 2025, will assess the safety, tolerability, pharmacokinetics and weight-loss efficacy of once-daily oral dosing over a 13-week period. VK2375 is being developed in oral and subcutaneous formulations. The target population consists of adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid study's primary endpoint is the percent change in body weight from baseline after 13 weeks of treatment. Secondary and exploratory endpoints will evaluate additional safety and efficacy measures. Viking expects to release results in the second half of 2025, with William Blair projecting an August readout. Analyst Andy Hsieh wrote Tuesday, 'Our base-case expectation is to replicate the 4-week Phase I results, translating to a placebo-adjusted weight loss of slightly under 7% for the highest doses.' Hsieh highlighted the advantage of using the same active ingredient across oral and injectable formats, allowing patients to switch between the two without increasing the risk of new side effects. William Blair reiterated its Outperform rating on Viking shares. Given the underwhelming weight loss magnitude from Eli Lilly and Co.'s (NYSE:LLY) Phase 3 ATTAIN-1 trial of orforglipron, coupled with potential uncertainties associated with the persistent rate of adverse events, the analyst believes the setback creates a clinical void for smaller competitors to fill. 'We expect Viking to rise to the occasion and demonstrate the potential of the oral tablet formulation of VK2735 as a competitive option in the maintenance setting. We therefore would be buyers before the Phase II VENTURE-oral readout,' William Blair wrote in an investor note on Tuesday. In June, Viking Therapeutics initiated the VANQUISH Phase 3 clinical program for subcutaneous VK2735. In 2024, Viking announced topline results from the Phase 2 VENTURE study of subcutaneous VK2735 in obesity. Patients receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7%, and statistically significant reductions in mean body weight relative to placebo, ranging up to 13.1%. Price Action: VKTX stock is trading higher by 2.38% to $40.81 at last check Wednesday. Read Next:Image via Shutterstock Latest Ratings for VKTX Date Firm Action From To Feb 2022 Raymond James Maintains Outperform Jul 2021 Raymond James Maintains Outperform May 2021 Raymond James Downgrades Strong Buy Outperform View More Analyst Ratings for VKTX View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store